Your fact-checks will appear here
The development and review of drugs for treating Alzheimer's disease, including 182 clinical trials and 138 drugs in 2025
Clinical and preclinical literature describes repeated low-dose methylene blue (MB) as a candidate neuroprotective and memory‑enhancing agent via mitochondrial and anti‑oxidant actions, with human ima...
Honey shows biological properties—antioxidant, anti-inflammatory, and polyphenol-driven activities—that lab studies and animal models suggest could be neuroprotective and might modestly affect pathway...
Approved, peer‑tested dementia treatments that have shown measurable slowing of cognitive decline in human trials remain the best-evidenced options today, while the interventions Elon Musk has promote...